Abstract
Anthracyclines show anti myeloma effects, being part of active regimens like infusional vincristine/ doxorubicin/ pulsed dexamethasone (VAD) in the past and recently of bortezomib/doxorubicin/pulsed dexamethasone (PAD) for the treatment of multiple myeloma. The recent introduction of pegylated liposomal doxorubicin has led to the development of newer anthracycline-containing regimens with improved toxicity profiles.
In vitro, anthracyclines are able of suppressing bortezomib-mediated induction of some stress response proteins with a large synergic effect. Clinical trials have shown impressive activity of pegylated liposomal doxorubicin and conventional doxorubicin in combination with bortezomib in patients with relapsed/refractory myeloma. Herein, we review the clinical data supporting the use of pegylated liposomal doxorubicin combined to active agents in salvage regimens for relapsed/ refractory multiple myeloma patients.
Keywords: Multiple myeloma, relapse, doxorubicin, salvage chemotherapy.
Current Cancer Therapy Reviews
Title:Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Volume: 9 Issue: 1
Author(s): Alessandra Romano, Giuseppina Uccello, Paolo Spina, Rosario Cunsolo, Calogero Vetro and Francesco Di Raimondo
Affiliation:
Keywords: Multiple myeloma, relapse, doxorubicin, salvage chemotherapy.
Abstract: Anthracyclines show anti myeloma effects, being part of active regimens like infusional vincristine/ doxorubicin/ pulsed dexamethasone (VAD) in the past and recently of bortezomib/doxorubicin/pulsed dexamethasone (PAD) for the treatment of multiple myeloma. The recent introduction of pegylated liposomal doxorubicin has led to the development of newer anthracycline-containing regimens with improved toxicity profiles.
In vitro, anthracyclines are able of suppressing bortezomib-mediated induction of some stress response proteins with a large synergic effect. Clinical trials have shown impressive activity of pegylated liposomal doxorubicin and conventional doxorubicin in combination with bortezomib in patients with relapsed/refractory myeloma. Herein, we review the clinical data supporting the use of pegylated liposomal doxorubicin combined to active agents in salvage regimens for relapsed/ refractory multiple myeloma patients.
Export Options
About this article
Cite this article as:
Romano Alessandra, Uccello Giuseppina, Spina Paolo, Cunsolo Rosario, Vetro Calogero and Raimondo Di Francesco, Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients, Current Cancer Therapy Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573394711309010001
DOI https://dx.doi.org/10.2174/1573394711309010001 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: State of the Art
Current Respiratory Medicine Reviews Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Current Concepts on Prenatal Diagnosis and Management of Fetal Tachyarrythmias
Current Cardiology Reviews The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress
Current Cardiology Reviews Recent Advances in Molecular Modeling and Medicinal Chemistry Aspects of Phospho-Glycoprotein&#
Current Drug Metabolism Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry Role of Chemokines and Trafficking of Immune Cells in Parasitic Infections
Current Immunology Reviews (Discontinued) Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms
Current Cardiology Reviews Oxidative Stress and Drugs of Abuse: An Update
Mini-Reviews in Organic Chemistry Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design